Cytoseek’s novel cell membrane augmentation technology enables the addition of new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability.
A spin-out from the University of Bristol, CytoSeek’s technology is based on the research of Dr Adam Perriman, who pioneered a new methodology for the rational design of synthetic artificial membrane-binding proteins.
